Read More Pharma Industry News Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth. bySoujanya RaviJune 6, 2026